Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2060

Sort by

Sort Order Select

Journal Articles

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Blood (2021) 137 (20): 2785–2799.

https://doi.org/10.1182/blood.2020005244

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Tomoyasu Jo, Momoko Nishikori, Yasunori Kogure, Hiroshi Arima, Katsuhiro Sasaki, Yoshiteru Sasaki, Tomoko Nakagawa, Fumie Iwai, Shuji Momose, Aki Shiraishi, Hiroshi Kiyonari, Noritaka Kagaya, Tetsuo Onuki, Kazuo Shin-ya, Minoru Yoshida, Keisuke Kataoka, Seishi Ogawa, Kazuhiro Iwai, Akifumi Takaori-Kondo

Blood (2020) 136 (6): 684–697.

https://doi.org/10.1182/blood.2019002654

Published: 2020

Includes: Supplemental data

Journal Articles

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Blood (2020) 135 (11): 862–865.

https://doi.org/10.1182/blood.2019002920

Published: 2020

Journal Articles

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Anne Durandy, Sven Kracker

Blood (2020) 135 (9): 638–643.

https://doi.org/10.1182/blood.2019002072

Published: 2020

Journal Articles

Distinct molecular profile of IRF4 -rearranged large B-cell lymphoma

Blood (2020) 135 (4): 274–286.

https://doi.org/10.1182/blood.2019002699

Published: 2020

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Katarzyna Aleksandra Jalowiec, Thomas Pabst, MD, Christoph Bocksrucker, Claudio Brunold, Barbara Jeker, Gabriela M Baerlocher, MD, Urban Novak, Ulrike Bacher, Michael Daskalakis, MD, Behrouz Mansouri, MD, Sacha S Zeerleder, MD PhD

Blood (2019) 134 (Supplement_1): 2457.

https://doi.org/10.1182/blood-2019-126534

Published: 2019

Journal Articles

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Rami Alsharif, MD, Samah Nassereddine, MD, Esma Akin, MD, Donald Karcher, MD, Mitchell Smith, MD PhD, Eduardo Sotomayor, MD, Kieron Dunleavy, MD

Blood (2019) 134 (Supplement_1): 5355.

https://doi.org/10.1182/blood-2019-124081

Published: 2019

Journal Articles

A Randomized Controlled Clinical Study of Peg-Rhg-CSF for Preventing Chemotherapy-Induced Neutropenia in Patients with B-Cell Non-Hodgkin Lymphoma

Changqing Zhen, MD, Mei Ding, Kang Lu, MD PhD, Xueling Ge, PhD, Na Chen, MD, Xiaosheng Fang, MD, Xiaohui Sui, Jiang Yujie, MD, Xin Liu, Ying Li, Xianghua Wang, Ying Li, MD, Lingyan Zhang, MD, Hongzhi Xu, Juan Fan, MD, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 5323.

https://doi.org/10.1182/blood-2019-128438

Published: 2019

Journal Articles

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Shonali Midha, MD, Julio C. Chavez, MD, Hayder Saeed, MD, Celeste Bello, MD, Farhad Khimani, MD, Silvia Tse Bunting, MD MSc, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5347.

https://doi.org/10.1182/blood-2019-130721

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Eleanor Lucas, BA, Beth Lesher, PharmD, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5831.

https://doi.org/10.1182/blood-2019-129677

Published: 2019

Journal Articles

From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology

Ivan Maillard, MD PhD

Blood (2019) 134 (Supplement_1): SCI-47.

https://doi.org/10.1182/blood-2019-121067

Published: 2019

Journal Articles

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Maher K. Gandhi, PhD

Blood (2019) 134 (Supplement_1): SCI-8.

https://doi.org/10.1182/blood-2019-121284

Published: 2019

Journal Articles

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1478.

https://doi.org/10.1182/blood-2019-129136

Published: 2019

Journal Articles

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Alex Vasuthasawat, BS, MS, Reiko E Yamada, Kham R Trinh, Neiki Rokni, Sherie L Morrison, PhD, John M. Timmerman, MD

Blood (2019) 134 (Supplement_1): 1575.

https://doi.org/10.1182/blood-2019-131890

Published: 2019

Journal Articles

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Katrin Pansy, MSc, BSc, Julia Feichtinger, Barbara Ehall, Barbara Uhl, Hildegard T. Greinix, MD, Katharina Prochazka, MD, Christine Beham-Schmid, Peter Neumeister, MD, Tanja Wrodnigg, Karoline Fechter, Alexander Deutsch

Blood (2019) 134 (Supplement_1): 1519.

https://doi.org/10.1182/blood-2019-130029

Published: 2019

Journal Articles

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Adam Yuh Lin, MD PhD, Jonathan Rink, PhD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 1577.

https://doi.org/10.1182/blood-2019-125308

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma

Distinct molecular profile of IRF4 -rearranged large B-cell lymphoma

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

How to Collect the Minimum-Targeted CD3+ Cells for CAR-T Therapy- the Bern Approach

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

A Randomized Controlled Clinical Study of Peg-Rhg-CSF for Preventing Chemotherapy-Induced Neutropenia in Patients with B-Cell Non-Hodgkin Lymphoma

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)

From Graft-Versus-Host Disease to Lymphoma Pathogenesis: Emerging Roles for Stromal Notch Ligands in Hematology

A Complicated Neighborhood: Insights into the Hodgkin Lymphoma Microenvironment

Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells

Deregulated CXCR4-CXCL12 Signaling Impacts on the Pathogenesis of DLBCL

Engineering CpG Deoxynucleotide-Conjugated Gold Nanoparticles for Enhanced Anti-Lymphoma Effects in an Immune Competent Lymphoma Model

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only